WO1995032731A3 - Immunogenic pharmaceuticals - Google Patents

Immunogenic pharmaceuticals Download PDF

Info

Publication number
WO1995032731A3
WO1995032731A3 PCT/GB1995/001274 GB9501274W WO9532731A3 WO 1995032731 A3 WO1995032731 A3 WO 1995032731A3 GB 9501274 W GB9501274 W GB 9501274W WO 9532731 A3 WO9532731 A3 WO 9532731A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
pharmaceuticals
mutation
immunogenic
mutant protein
Prior art date
Application number
PCT/GB1995/001274
Other languages
French (fr)
Other versions
WO1995032731A2 (en
Inventor
Alain Robert Michael Townsend
Original Assignee
Univ Oxford
Medical Res Council
Alain Robert Michael Townsend
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford, Medical Res Council, Alain Robert Michael Townsend filed Critical Univ Oxford
Priority to JP8500539A priority Critical patent/JPH10504702A/en
Priority to EP95921028A priority patent/EP0762891A1/en
Priority to AU26237/95A priority patent/AU2623795A/en
Publication of WO1995032731A2 publication Critical patent/WO1995032731A2/en
Publication of WO1995032731A3 publication Critical patent/WO1995032731A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

There are disclosed pharmaceuticals which comprise either part or all of a polypeptide or a nucleotide sequence coding for said part or all of a polypeptide which polypeptide is substantially homologous to a mutant protein produced in consequence of its mutation in a gene sequence which shifts translation from the gene sequence out of the list reading enzyme into either the second or third reading frames downstream of the mutation and which said part or all of a polypeptide is able to involve an immune response against the mutant protein.
PCT/GB1995/001274 1994-06-01 1995-06-01 Immunogenic pharmaceuticals WO1995032731A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP8500539A JPH10504702A (en) 1994-06-01 1995-06-01 Immunogen preparation
EP95921028A EP0762891A1 (en) 1994-06-01 1995-06-01 Immunogenic pharmaceuticals
AU26237/95A AU2623795A (en) 1994-06-01 1995-06-01 Immunogenic pharmaceuticals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9410922A GB9410922D0 (en) 1994-06-01 1994-06-01 Vaccines
GB9410922.0 1994-06-01

Publications (2)

Publication Number Publication Date
WO1995032731A2 WO1995032731A2 (en) 1995-12-07
WO1995032731A3 true WO1995032731A3 (en) 1995-12-21

Family

ID=10755982

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1995/001274 WO1995032731A2 (en) 1994-06-01 1995-06-01 Immunogenic pharmaceuticals

Country Status (5)

Country Link
EP (1) EP0762891A1 (en)
JP (1) JPH10504702A (en)
AU (1) AU2623795A (en)
GB (1) GB9410922D0 (en)
WO (1) WO1995032731A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012992A2 (en) * 1995-10-02 1997-04-10 Royal Netherlands Academy Of Arts And Sciences Diagnosis method for a disease caused by a frameshift mutation in a gene and reagents therefore
JP2001522241A (en) * 1997-04-10 2001-11-13 ロイヤル ネザーランズ アカデミー オブ アーツ アンド サイエンシズ Diagnostic methods and reagents
NO315238B1 (en) * 1998-05-08 2003-08-04 Gemvax As Peptides derived from reading frame shift mutations in the TBF <beta> II or BAX gene, and pharmaceutical compositions containing them, nucleic acid sequences encoding such peptides, plasmids, and virus vector-encompassing such nucleic acid
NO314086B1 (en) * 1998-05-08 2003-01-27 Gemvax As Peptides and pharmaceutical compositions containing them, nucleic acid sequences encoding such peptides, plasmids and virus vectors encompassing such DNA sequences and their use for the preparation of pharmaceutical preparations for
ITMI20030434A1 (en) 2003-03-07 2004-09-08 Istituto Oncologico Romagnolo Coope Rativa Sociale METHOD FOR THE DETECTION OF COLON-RECTUM TUMORS.
JP2009532664A (en) * 2006-02-27 2009-09-10 アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティ Identification and use of novopeptides for the treatment of cancer
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
EP3075389A1 (en) * 2015-03-31 2016-10-05 Technische Universität München T cell receptors and peptides derived by mutations for the treatment of cancer
CA3065325A1 (en) 2017-06-02 2018-12-06 Arizona Board Of Regents On Behalf Of Arizona State University A method to create personalized cancer vaccines
GB201710812D0 (en) * 2017-07-05 2017-08-16 Francis Crick Inst Ltd Method
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
WO2020022901A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for uterine cancer
EP3827263A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for colorectal cancer
WO2020022897A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
WO2020022903A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN VACCINES FOR CANCER
EP3827265A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for kidney cancer
US20210162032A1 (en) 2018-07-26 2021-06-03 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687737A (en) * 1982-11-12 1987-08-18 Massachusetts Institute Of Technology Mammalian suppressor genes
EP0565794A1 (en) * 1992-04-14 1993-10-20 British Biotech Pharmaceuticals Limited Induction of CTL responses
WO1994010323A1 (en) * 1992-11-04 1994-05-11 Imperial Cancer Research Technology Limited Virus with modified binding moiety specific for the target cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687737A (en) * 1982-11-12 1987-08-18 Massachusetts Institute Of Technology Mammalian suppressor genes
EP0565794A1 (en) * 1992-04-14 1993-10-20 British Biotech Pharmaceuticals Limited Induction of CTL responses
WO1994010323A1 (en) * 1992-11-04 1994-05-11 Imperial Cancer Research Technology Limited Virus with modified binding moiety specific for the target cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AKIRA HORII ET AL.: "The APC gene , responsible for familial adenomatous polyposis , is mutated in human gastric cancer", CANCER RESEARCH, vol. 52, pages 3231 - 3233 *
HARRIS C.C. ET AL.: "Clinical implications of the p53 tumor-suppressor gene", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 329, no. 18 *
ROY N: "Generation of influenza-specific cytotoxic T-lymphocytes by retroviral gene transfer.", DISS ABSTR INT [B];54(3):1242 1993 *
YASUO MIYOSHI ET AL.: "Somatic mutations of the APC gene in colrectal tumors : mutation cluster region in the APC gene", HUMAN MOLECULAR GENETICS, vol. 1, no. 4, pages 229 - 233 *

Also Published As

Publication number Publication date
JPH10504702A (en) 1998-05-12
GB9410922D0 (en) 1994-07-20
AU2623795A (en) 1995-12-21
WO1995032731A2 (en) 1995-12-07
EP0762891A1 (en) 1997-03-19

Similar Documents

Publication Publication Date Title
WO1995032731A3 (en) Immunogenic pharmaceuticals
GR3022124T3 (en) A yeast cell of the genus schwanniomyces
WO1994026906A3 (en) Cloned dna encoding a udp-galnac:polypeptide,n-acetylgalactos aminyltransferase
DE69529219D1 (en) Helicobacter proteine und impstoffe
CA2240334A1 (en) Thermostable dna polymerase from thermoanaerobacter thermohydrosulfuricus and mutant enzymes thereof with exonuclease activity removed
AU657487B2 (en) Nucleotide sequence coding for an outer membrane protein from neisseria meningitidis and use of said protein in vaccine preparations
DE69534875D1 (en) CALCIUM-FREE SUBTILISIN MUTANT
WO1996022308A3 (en) Appetite suppression factor and related methods
EP1688500A3 (en) Overexpression of phytase genes in yeast systems
NZ335628A (en) Improved expression vectors comprising a nucleic acid construct with tac and gal bacterial promoters
CA2124214A1 (en) Materials and methods for biosynthesis of serine and serine-related products
WO1998021341A3 (en) Method for the recombinant production of 1,3-propanediol
AU4178800A (en) Hydantoinase variants with improved properties and their use for the production of amino acids
CA2252493A1 (en) .beta.-galactoside - .alpha. 2,6-sialyltransferase gene
AU8258591A (en) Human mk gene and protein sequence
WO1996034964A3 (en) Stable variant hk2 polypeptide
DE69014046D1 (en) Branching enzyme and its use.
AU7001994A (en) Mutant polypeptide of protein kinase c, nucleic acid sequences coding for said polypeptide and use thereof
EP0331356A3 (en) Expression of hiv binding proteins
HU9801384D0 (en) Clostridium perfringeus vaccine
HUP0203221A2 (en) Genes encoding enzymes for lignin biosynthesis and uses thereof
EP0736602A3 (en) Siaalpha 2,3Ga1beta 1, 4G1cNAc alpha 2,8-sialyltransferase
AU3950799A (en) Genetically engineered yeast and mutants thereof for the efficient fermentation of lignocellulose hydrolysates
WO2001079489A3 (en) 39228, a human alcohol dehydrogenase and uses therefor
ATE103979T1 (en) HUMAN LYMPHOTOXIN.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995921028

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 750236

Date of ref document: 19970129

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1995921028

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1995921028

Country of ref document: EP